JHLT open · 2026
Comparison of donor-derived cell-free DNA fractions between combined heart-lung vs isolated heart or lung transplant recipients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pasupneti Shravani, Valentine Vincent, Mudgett Hannah, Fan Chun-Po Steve, Mann Emerald, Zhou Mingming, Shen Ling, Henricksen Erik, Khush Kiran, Hanson Paul, MacArthur J W, Levine Deborah, Dhillon Gundeep
Аннотация
BACKGROUND: Donor-derived cell-free DNA (dd-cfDNA) is a validated marker of graft injury following isolated heart or lung transplantation. However, no such studies exist for heart-lung transplant (HLTx) recipients.
METHODS: HLTx recipients at a single center were screened for enrollment between August 2022 and September 2024. Heart transplant (HTx) and lung transplant (LTx) recipients from the same center served as comparison groups. Plasma dd-cfDNA samples were collected before surveillance bronchoscopies and clinically indicated evaluation for graft dysfunction during the first-year post-transplant. Stable patients demonstrated no evidence of rejection, infection, or injury at any time. Pulmonary function test results (PFTs) were monitored and compared.
RESULTS: In total, 92 HTx, 39 LTx, and 10 HLTx recipients were enrolled. The HLTx cohort had a significantly different dd-cfDNA profile compared to LTx and HTx (median dd-cfDNA in HLTx: 0.14, LTx: 0.34, and HTx: 0.06, p<0.001), with values lower than LTx in both stable and unstable groups. One-year post-transplant, 31% of HLTx patients were unstable, compared to 84% of LTx recipients. Acute rejection occurred in 10%, 10.5%, and 22.3%, of the HLTx, HTx, and LTx cohorts, respectively. PFTs at 1-year were also significantly different; in the HLTx group, percent predicted FEV1 values were increasing, but these parameters were decreasing in the LTx cohort.
CONCLUSIONS: This study indicates that dd-cfDNA could be a useful tool for monitoring allograft health following HLTx, though sample size was limited. Further research is underway to elucidate the mechanisms that account for these findings and to establish thresholds for detecting graft injury in this distinct cohort.
METHODS: HLTx recipients at a single center were screened for enrollment between August 2022 and September 2024. Heart transplant (HTx) and lung transplant (LTx) recipients from the same center served as comparison groups. Plasma dd-cfDNA samples were collected before surveillance bronchoscopies and clinically indicated evaluation for graft dysfunction during the first-year post-transplant. Stable patients demonstrated no evidence of rejection, infection, or injury at any time. Pulmonary function test results (PFTs) were monitored and compared.
RESULTS: In total, 92 HTx, 39 LTx, and 10 HLTx recipients were enrolled. The HLTx cohort had a significantly different dd-cfDNA profile compared to LTx and HTx (median dd-cfDNA in HLTx: 0.14, LTx: 0.34, and HTx: 0.06, p<0.001), with values lower than LTx in both stable and unstable groups. One-year post-transplant, 31% of HLTx patients were unstable, compared to 84% of LTx recipients. Acute rejection occurred in 10%, 10.5%, and 22.3%, of the HLTx, HTx, and LTx cohorts, respectively. PFTs at 1-year were also significantly different; in the HLTx group, percent predicted FEV1 values were increasing, but these parameters were decreasing in the LTx cohort.
CONCLUSIONS: This study indicates that dd-cfDNA could be a useful tool for monitoring allograft health following HLTx, though sample size was limited. Further research is underway to elucidate the mechanisms that account for these findings and to establish thresholds for detecting graft injury in this distinct cohort.